Advertisement
LUNG vs UTMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LUNG is a StrongBuy and UTMD is a Hold.
LUNG in upward trend: price may jump up because it broke its lower Bollinger Band on October 06, 2026
LUNG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 33 cases where LUNG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 58 cases where LUNG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LUNG as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
LUNG moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for LUNG entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.005) is normal, around the industry mean (2.923). P/E Ratio (-1.591) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for UTMD turns positive, indicating new upward trend
UTMD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned positive. In 62 of the 101 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTMD advanced for three days, in 144 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The 10-day RSI Indicator for UTMD moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 12 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for UTMD turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 29 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. UTMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.943) is normal, around the industry mean (4.952). P/E Ratio (22.780) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (5.980) is also within normal values, averaging (4.143). Dividend Yield (0.017) settles around the average of (0.005) among similar stocks. P/S Ratio (6.549) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
LUNG | UTMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 75 | |
PRICE GROWTH RATING 1..100 | 39 | 43 | |
P/E GROWTH RATING 1..100 | 80 | 12 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LUNG's Valuation (35) in the null industry is somewhat better than the same rating for UTMD (86) in the Medical Specialties industry. This means that LUNG’s stock grew somewhat faster than UTMD’s over the last 12 months.
LUNG's Profit vs Risk Rating (100) in the null industry is in the same range as UTMD (100) in the Medical Specialties industry. This means that LUNG’s stock grew similarly to UTMD’s over the last 12 months.
UTMD's SMR Rating (75) in the Medical Specialties industry is in the same range as LUNG (98) in the null industry. This means that UTMD’s stock grew similarly to LUNG’s over the last 12 months.
LUNG's Price Growth Rating (39) in the null industry is in the same range as UTMD (43) in the Medical Specialties industry. This means that LUNG’s stock grew similarly to UTMD’s over the last 12 months.
UTMD's P/E Growth Rating (12) in the Medical Specialties industry is significantly better than the same rating for LUNG (80) in the null industry. This means that UTMD’s stock grew significantly faster than LUNG’s over the last 12 months.
| LUNG | UTMD | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 57% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 58% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 50% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 58% |
| Advances ODDS (%) | 2 days ago 80% | 3 days ago 58% |
| Declines ODDS (%) | 4 days ago 84% | 18 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LUNG’s FA Score shows that 0 FA rating(s) are green while UTMD’s FA Score has 1 green FA rating(s).
- LUNG’s FA Score: 0 green, 5 red.
- UTMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LUNG’s TA Score shows that 4 TA indicator(s) are bullish while UTMD’s TA Score has 2 bullish TA indicator(s).
- LUNG’s TA Score: 4 bullish, 5 bearish.
- UTMD’s TA Score: 2 bullish, 4 bearish.
Price Growth
LUNG (@Medical/Nursing Services) experienced а +2.81% price change this week, while UTMD (@Pharmaceuticals: Other) price change was -0.09% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.63%. For the same industry, the average monthly price growth was -3.82%, and the average quarterly price growth was +8.73%.
Reported Earning Dates
LUNG is expected to report earnings on Oct 27, 2026.
UTMD is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
UTMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, UTMD has been loosely correlated with CERS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if UTMD jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To UTMD | 1D Price Change % | ||
|---|---|---|---|---|
| UTMD | 100% | -0.47% | ||
| CERS - UTMD | 50% Loosely correlated | +3.46% | ||
| TMCI - UTMD | 47% Loosely correlated | +1.72% | ||
| INMD - UTMD | 47% Loosely correlated | -0.78% | ||
| ITGR - UTMD | 44% Loosely correlated | N/A | ||
| IART - UTMD | 43% Loosely correlated | -11.18% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CRPT | 14.89 | 0.73 | +5.16% |
| First Trust SkyBridge Crypto Industry & Digital Economy ETF (CRPT) | |||
| ISSB | 23.24 | 0.77 | +3.42% |
| IncomeSTKd 1x US Stocks & 1x Bitcoin Premium ETF (ISSB) | |||
| JHAI | 33.31 | 0.50 | +1.52% |
| Janus Henderson Global Artificial Intelligence ETF (JHAI) | |||
| ILDR | 38.16 | 0.29 | +0.77% |
| First Trust Innovation Leaders ETF (ILDR) | |||
| IHE | 102.78 | -0.69 | -0.67% |
| iShares U.S. Pharmaceuticals ETF (IHE) | |||